No-Touch Relief for Patients
Whose Skin Is Sensitive to the Touch
Patients with various forms of inflammatory dermatoses may have sensitive skin.1 KENALOG Spray is the only mid-potency topical steroid aerosol spray1 that provides no-touch relief with triamcinolone, 0.2%2 —delivered without having to touch the affected area.*
*After spraying, the nonvolatile vehicle remaining on the skin contains approximately triamcinolone acetonide, 0.2%. Each gram of spray provides triamcinolone acetonide, 0.147 g, in a vehicle of isopropyl palmitate; dehydrated alcohol, 10.3%, and isobutane propellant.2
Relief is within easy reach
Spray application makes it easier for patients to treat dermatitis on hard-to-reach areas of the body, which may improve adherence to therapy.1 KENALOG Spray can be applied at any angle for specific, broad coverage.
No rubbing in or greasy residual film
Unlike creams, ointments, foams, and other sprays, KENALOG Spray is proven to work without being rubbed in.3 And with KENALOG Spray, patients get true no-touch relief that doesn’t leave behind a messy, greasy film.
Available in 2 sizes
KENALOG Spray may be prescribed in both 63- or 100-g sizes, which offer extension nozzles for easier access to the scalp and other areas. Directions for use are provided on the label. The preparation may be applied to any area of the body, but when it is sprayed near the face, care should be taken to see that the eyes are covered and inhalation of the spray is avoided.
Patients prefer KENALOG Spray
In a clinical study evaluating efficacy of KENALOG Spray, patients were asked on day 28 whether they preferred KENALOG Spray or another product, such as cream or ointment.1
IMPORTANT SAFETY INFORMATIONINDICATIONS AND USAGE: KENALOG Spray (Triamcinolone Acetonide Topical Aerosol, USP) is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
SUMMARY OF RISK INFORMATION FOR KENALOG SPRAY
CONTRAINDICATIONS: Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.
PRECAUTIONS: Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients.
Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface area, prolonged use, and the addition of occlusive dressings.
Patients receiving a large dose of any topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression.
Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.
Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing’s syndrome than mature patients because of a larger skin surface area to body weight ratio.
Caution should be exercised when topical corticosteroids are administered to a nursing woman.
This preparation is not for ophthalmic, oral, or intravaginal use.
For topical use only. Please see Full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.